Yeh Edward T H
Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Annu Rev Med. 2006;57:485-98. doi: 10.1146/annurev.med.57.121304.131240.
Modern cancer therapy employs a combination of chemotherapy, antibody-based therapy, radiotherapy, and surgery to prolong life and provide cure. However, many of the chemotherapy agents and antibodies, either singly or in combination, can affect the cardiovascular system. Common cardiovascular manifestations of these therapies include heart failure, ischemia, hypotension, hypertension, edema, QT prolongation, bradyarrhythmia, and thromboembolism. The patient's age, underlying cardiovascular status, and genetic background, as well as the route of drug administration and dosage, can all contribute to the development of cardiotoxicity. Strategies to monitor for and to manage these effects are discussed in this review.
现代癌症治疗采用化疗、基于抗体的治疗、放疗和手术相结合的方法来延长生命并实现治愈。然而，许多化疗药物和抗体，无论是单独使用还是联合使用，都可能影响心血管系统。这些治疗常见的心血管表现包括心力衰竭、缺血、低血压、高血压、水肿、QT间期延长、缓慢性心律失常和血栓栓塞。患者的年龄、潜在的心血管状况、遗传背景，以及药物给药途径和剂量，都可能导致心脏毒性的发生。本综述讨论了监测和管理这些影响的策略。
